Key Highlights
- PropheSee™: AI-powered predictive model for continuous glucose monitoring (CGM) adherence.
- 50% Increase in Adherence: Targeted interventions improve adherence rates among high-risk patients.
- $2,200 Annual Savings: Health plans and providers benefit from better glycemic control.
- Comprehensive Patient Data: Utilizes proprietary patient behavior and SDOH data for accurate risk identification.
- Collaborative Development: Developed with Accenture, enhancing patient engagement and health outcomes.
Source: Business Wire
Notable Quotes
- “CCS can now proactively identify if a member is at a higher risk of falling off therapy, and then take action based on individual specific insights to best support them in maintaining adherence.” — Richard Mackey, CTO at CCS
- “The innovative, advanced analytics predictive model that Accenture collaborated with CCS to develop will help identify patients at risk of non-adherence to diabetic treatment up to 90 days in advance.” — Chinmoy Barua, Managing Director of Data & AI at Accenture
SoHC's Take
The launch of PropheSee™ marks a significant advancement in diabetes management, leveraging AI to enhance patient adherence to CGM devices. This innovative approach not only improves clinical outcomes but also offers substantial cost savings for healthcare organizations. The integration of extensive patient behavior data and social determinants of health insights underscores the model’s potential to proactively address adherence issues, making it a valuable tool in chronic care management. The collaboration with Accenture further strengthens the model’s predictive capabilities, promising better health outcomes and improved quality of life for patients.
